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Renin is an aspartic protease that consists of two
homologous lobes. The cleft in between contains
the active site with two catalytic aspartic residues.
Renin cleaves angiotensinogen, to generate
angiotensin I (Ang I). Ang I is the precursor of the
active end-product of the renin-angiotensin
system (RAS), angiotensin II (Ang II).
Renin has also been called active renin to
underline that an enzymatically inactive form of
renin exists: prorenin. Only with the cloning of
the renin gene in 1984, was prorenin definitively
proved to be the precursor of renin.1 For reasons
that are unknown, prorenin circulates in human
plasma in excess to renin, sometimes at
concentrations that are 100 times higher.2
A 43-amino acid N-terminal propeptide explains
the absence of enzymatic activity of prorenin.
This propeptide covers the enzymatic cleft and
obstructs access of angiotensinogen to the active
site of renin.
We provide here a synopsis of a recently published
paper on renin/prorenin and the renin receptor.3
Prorenin activation 
Prorenin can be activated in two ways:
proteolytic or non-proteolytic. Proteolytic
activation involves actual removal of the
propeptide. In vivo, proteolytic activation of
prorenin occurs in the kidney. Bolus infusions of
recombinant human prorenin in monkeys did not
provide evidence for prorenin-renin conversion
in the circulation.4
Non-proteolytic activation of prorenin is a
reversible process. It can best be imagined as an
unfolding of the propeptide from the enzymatic
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cleft (Figure 1). This unfolding consists of at least
two steps. In the first step the propeptide moves
out of the enzymatic cleft, and in the second step
the renin part of the molecule assumes its
enzymatically active conformation.5 Non-
proteolytic activation can be induced by exposure
to low pH (with an optimum at pH 3.3) and cold,
called acid activation and cryoactivation,
respectively.6,7 Acid activation leads to complete
activity of prorenin, cryoactivation to partial
(~15%) activity.
Non-proteolytically activated prorenin is
enzymatically fully active, and can be recognised
by monoclonal antibodies that are specific for the
active site. Remarkably, these antibodies also
recognised prorenin following incubation with a
renin inhibitor.5 Application of monoclonal
antibodies against the propeptide after prorenin
exposure to a renin inhibitor confirmed that,
under these conditions, the prosegment was still
present.8 Thus, renin inhibitors, like low pH and
cold, are capable of non-proteolytically
‘activating’ prorenin, although of course, due to
the presence of the renin inhibitor, this activated
prorenin cannot display enzymatic activity
(Figure 1).
Measurement of renin and prorenin
Two types of assays exist for measurement of
renin. The first one employs the enzymatic
activity of renin: the plasma renin activity (PRA)
assay. It is performed by incubating plasma in the
presence of inhibitors of Ang I-degrading
enzymes. The generated Ang I is an index of
renin activity. This generation depends not only
on the amount of renin but also on the
angiotensinogen concentration in plasma.
The second type of renin assay is a direct
immunoassay. Three assays are currently
marketed, an immunoradiometric assay (IRMA) by
Cis Bio,9 and two assays by Nichols Diagnostics,10,11
an IRMA and a chemoluminometric assay that runs
on an automated platform. All three assays use an
immobilised capture antibody that binds both
renin and prorenin. The second, developing
antibody is specific for renin and is labelled by
either radioactive iodine for the IRMA or
acridinium for the chemoluminometric assay.
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All renin assays may overestimate renin because
of the presence of cryoactivated prorenin.
Samples should therefore never be left on ice for
prolonged periods of time.
Prorenin can be measured indirectly by
performing a renin assay after converting
prorenin to renin (proteolytic or non-
proteolytic).5,8 The results of this assay will reflect
total renin levels, i.e. the levels of prorenin plus
renin. Subtracting the renin level from the total
renin level is then a measure of prorenin.
Tissue renin
Local synthesis of angiotensins at tissue sites,
independent of angiotensin generation in the
circulation, is now widely accepted.12,13
Interference with such locally synthesised Ang II
may in fact underlie the beneficial effects of RAS
blockers. For a long time it was thought that local
angiotensin synthesis, e.g. in the heart, depended
on locally synthesised renin. Although renin is
indeed present in cardiac tissue,14,15 there is no
evidence for its local synthesis in the heart. Thus,
it appears that the renin required for cardiac
angiotensin generation is taken up from the
circulation, i.e., is kidney-derived. A similar
concept applies to the vascular wall.16
An attractive concept is that, in tissues not
synthesising renin locally, circulating prorenin,
following its local activation, contributes to
angiotensin generation. This would not only
provide a role for prorenin in vivo, but also
explain why tissues, in contrast to plasma,
contain predominantly renin.14 In support of this
concept, transgenic rodents with (inducible)
prorenin expression in the liver display increased
cardiac Ang I levels, cardiac hypertrophy and/or
vascular damage.17,18
Sequestration of circulating
(pro)renin: diffusion or a receptor-
mediated process?
The cardiac renin levels per se are too high to be
explained based upon the amount of (renin- and
prorenin-containing) blood plasma in the heart.14,15
Thus, circulating renin and prorenin either diffuse
into the interstitial space19 and/or bind to (pro)renin
receptors. In support of the latter, part of cardiac
renin is membrane-associated.14,20 Moreover,
isolated perfused hearts of rats transgenic for
human angiotensinogen release Ang I during renin
perfusion and this release continues after stopping
the renin perfusion.21 These data support the idea
that circulating renin binds to a cardiac renin-
binding protein/receptor, and that bound renin is
catalytically active.
The idea of renin binding is not new. In fact,
evidence for renin binding was already obtained
20 years ago, when it was observed that vascular
renin disappeared more slowly than circulating
renin following a bilateral nephrectomy.22
(Pro)renin receptors
Currently, two (pro)renin receptors have been
identified.23,24 The mannose-6-phosphate (M6P)
receptor binds renin and prorenin with high affinity
in cardiomyocytes,23 fibroblasts,23 and endothelial
cells.25 This receptor is identical to the insulin-like
growth factor II (IGFII) receptor, and as such it
contains binding domains for both IGFII and
phosphomannosylated (M6P-containing) proteins
like renin and prorenin. Following binding, renin
and prorenin are rapidly internalised, and
internalised prorenin is proteolytically cleaved to
renin.25 (Pro)renin binding to M6P/IGFII receptors
did not result in angiotensin generation,25,26 and
(prorenin-derived) intracellular renin was found to
be degraded slowly.25 Thus, M6P/IGFII receptors
most likely serve as clearance receptors for both
renin and prorenin.
Nguyen et al. and Sealey et al., using
radiolabelled (pro)renin, demonstrated high-
affinity renin binding sites/receptors in human
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Figure 2 Cell surface angiotensin (Ang) generation by prorenin is a
highly efficient process. Once generated, Ang II rapidly binds to
nearby AT1 receptors, without leaking into the extracellular space. 
Aog = angiotensinogen.  
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Figure 1 Proteolytic and non-proteolytic activation of prorenin. A renin
inhibitor will increase the amount of non-proteolytically activated
prorenin. Such a drug binds to prorenin when it is in its open, active
conformation. Once bound, the prosegment cannot regain its original
‘closed’ position, and thus prorenin will now be recognised by antibodies
directed against the active site, although of course it is incapable of
generating angiotensin (Ang) I from angiotensinogen (Aog). Due to the
high affinity of the renin inhibitor, prorenin will stay in the ‘open’
conformation, and thus the equilibrium will shift into the direction of the
open conformation. Eventually, all prorenin will be in the open
conformation. Reproduced with permission from reference 3.
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mesangial cells and in membranes prepared from
rat tissues, respectively.27,28 Cloning revealed that
the receptor is a 350-amino-acid protein with a
single transmembrane domain.24
The cloned renin receptor was found to bind
prorenin equally well, and receptor-bound prorenin
became enzymatically active in a non-proteolytic
manner. These data support angiotensin generation
on the cell surface (Figure 2).26
Based on experiments with a series of antibodies
directed against various parts of the prosegment,
Suzuki et al.7 recently proposed that human
prorenin has so-called ‘gate’ and ‘handle’ regions
for its non-proteolytic activation. According to
this concept, the handle region interacts with a
putative receptor, which then leads to
dissociation of the gate region from the renin
molecule. Since this gate region is crucial for
refolding and the maintenance of the inactive
state, dissociation allows prorenin to display
enzymatic activity. In a subsequent in vivo study,
these investigators applied a decoy peptide
corresponding to the handle region to block non-
proteolytic prorenin activation.29 This peptide
reduced the renal content of Ang I and II and
fully prevented the development of diabetic
nephropathy in streptozotocin-induced diabetic
rats. Thus, these data are the first to confirm that
endogenous prorenin contributes to tissue Ang I
and II generation in diabetic animals via a
mechanism involving binding of its handle region
to a receptor. It is tempting to speculate that this
receptor is the above-mentioned (pro)renin
receptor, but this remains to be proven.
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